Skip to Content
Skip to main content
LOGO(small) - Queen's University Belfast
  • Our twitter
  • Our
  • Our
  • Our
SEARCH SEARCH
LOGO(large) - Queen's University Belfast

Centre for Public Health

  • Home
  • About
    • About Us
    • Education
    • Find a PhD Supervisor
  • Research
    • Cancer Epidemiology
    • Epidemiology & Public Health
    • Health Services & Global Health
    • Public Health Nutrition and Metabolism
  • Events
  • News
  • Contact Us
    • Staff
  • Related Links
  • Home
  • About
    • About Us
    • Education
    • Find a PhD Supervisor
  • Research
    • Cancer Epidemiology
    • Epidemiology & Public Health
    • Health Services & Global Health
    • Public Health Nutrition and Metabolism
  • Events
  • News
  • Contact Us
    • Staff
  • Related Links
  • Our twitter
  • Our
  • Our
  • Home
  • Centre for Public Health
  • Research
  • Health Services & Global Health
  • Eye and Vision
  • IVAN
In This Section
  • Meet our team
  • PROSPER
  • BOOST
  • EAGLE
  • IVAN
  • THRIVE

IVAN

IVAN trial proves that a cheaper drug (bevacizumab/Avastin) is as good as the much more expensive ranibizumab/Lucentis for treating neovascular age-related macular degeneration

Eye and Vision
  • Eye and Vision
  • Meet our team
  • PROSPER
  • BOOST
  • EAGLE
  • IVAN
  • THRIVE
Queen's University Belfast - Logo (small)
Contact Us

Centre for Public Health
Institute of Clinical Sciences
Royal Victoria Hospital
Belfast
BT12 6BA

Phone: +44 (0) 28 9097 6350

Quick Links

  • Home
  • Research
  • About

 

© Queen's University Belfast 2021
Privacy and cookies
Website accessibility
Freedom of information
Modern slavery statement
Equality, Diversity and Inclusion